the combination of careful clinical he diagnosis of DM, PM and NAM relies on the evaluation, an elevated creatine kinase combination of careful clinical evaluation, an level, electromyography and muscle elevated creatine kinase level, electromyography biopsy. and muscle biopsy. NAM is often associated with a history of statin exposure, and the presence of autoantibodies against HMG coenzyme reductase, or other muscle antigens. Justification PM: The Biotext (2004) review included PM: The Biotext (2004) review identified one Justification for evidence revised and one prospective case-series study of 35 prospective case-series study of 35 adults with updated (A) for Evidence adults with chronic refractory chronic refractory polymyositis. This study reported Category polymyositis. IVIg may be of benefit in clinical improvement in 71% of patients with these patients, improve mean muscle significant improvement in muscle power, muscle power and allow reduction in dose of disability scores and CK levels (p < 0.01). Steroid corticosteroid. Further research is dose could be reduced after IVIg (p < 0.05). Further needed. research is needed. DM: The Biotext (2004) review included DM: The Biotext (2004) review identified one one double-blind, placebo-controlled double-blind, placebo-controlled trial considered of considered of low quality of 15 low quality of 15 patients with biopsy-confirmed, patients with biopsy-confirmed, treatment-resistant dermatomyositis. IVIg treatment treatment-resistant dermatomyositis. combined with prednisone led to significant IVIg treatment combined with improvement in muscle strength and neuromuscular prednisone led to significant symptoms of patients in the intervention group (n =
the combination of careful clinical evaluation, an elevated creatine kinase level, electromyography and muscle biopsy. he diagnosis of DM, PM and NAM relies on the combination of careful clinical evaluation, an elevated creatine kinase level, electromyography and muscle biopsy. NAM is often associated with a history of statin exposure, and the presence of autoantibodies against HMG coenzyme reductase, or other muscle antigens. Justification for Evidence Category PM: The Biotext (2004) review included one prospective case-series study of 35 adults with chronic refractory polymyositis. IVIg may be of benefit in these patients, improve mean muscle power and allow reduction in dose of corticosteroid. Further research is needed. DM: The Biotext (2004) review included one double-blind, placebo-controlled considered of low quality of 15 patients with biopsy-confirmed, treatment-resistant dermatomyositis. IVIg treatment combined with prednisone led to significant PM: The Biotext (2004) review identified one prospective case-series study of 35 adults with chronic refractory polymyositis. This study reported clinical improvement in 71% of patients with significant improvement in muscle power, muscle disability scores and CK levels (p < 0.01). Steroid dose could be reduced after IVIg (p < 0.05). Further research is needed. DM: The Biotext (2004) review identified one double-blind, placebo-controlled trial considered of low quality of 15 patients with biopsy-confirmed, treatment-resistant dermatomyositis. IVIg treatment combined with prednisone led to significant improvement in muscle strength and neuromuscular symptoms of patients in the intervention group (n = Justification for evidence revised and updated (A)
inflammatory-myopathies-polymyositis%28pm%29-dermatomyositis%28dm%29-and-necrotising-autoimmune-myopathy%28nam%29.DOCX